Medical/Pharmaceuticals

VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone

SHANGHAI, May 23, 2022 /PRNewswire/ -- VISEN Pharmaceuticals, an innovative biopharmaceutical company focused on endocrine diseases, today announced positive top-line results from its pivotal phase 3 trial, a randomized, open-label, active-controlled trial that compared lonapegsomatropin (TransCo...

2022-05-23 15:57 1720

Hanmi Fine Chemical Launches 'high-tech CDMO' Business

CDMO business initiated such as mRNA vaccine raw materials·peptides 10 billion KRW invested in Hanmi Fine Chemical facility expansion SEOUL, South Korea, May 22, 2022 /PRNewswire/ -- Hanmi Fine Chemical (hereinafter Hanmi FC) a subsidiary of Hanmi Pharmaceutical Group specializing in APIs(Active...

2022-05-23 08:32 3153

WHO Goodwill Ambassador for Leprosy Elimination Recognized with WHO Director-General's Award for Global Health at 75th World Health Assembly

Ambassador will call on countries to strengthen efforts against leprosy in meetings with delegations attending WHA TOKYO, May 22, 2022 /PRNewswire/ -- WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa arrives inGeneva, Switzerland on May 23 for the 75th World Health Assembly, where ...

2022-05-23 00:00 2885

Meihua International Medical Technologies Co., Ltd. Receives Notification of Deficiency from Nasdaq Related to Delayed Annual Report on Form 20-F

YANGZHOU, China, May 20, 2022 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (NASDAQ: MHUA), a reputable manufacturer and provider of Class I, II, and III disposable medical devices with operating subsidiaries inChina, today announced that on May 18,...

2022-05-20 22:57 7887

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, May 19, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of can...

2022-05-19 22:39 3179

I-Mab to Hold Investor Call to Report Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab

SHANGHAI and GAITHERSBURG, MD., May 19 , 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq" IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that it will hold a call with investors at 8 a.m. EST on...

2022-05-19 20:00 2477

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib's Therapeutic Potential in Treating COVID-19 Published in EMBO Molecular Medicine

SUZHOU, China and ROCKVILLE, Md., May 18, 2022 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a new preclinical study, conducted by the rese...

2022-05-18 22:06 3144

OriCiro Genomics expand into Boston, Open new office in North America

TOKYO, May 18, 2022 /PRNewswire/ -- OriCiro Genomics K.K. a pioneer in cell-free synthesis and amplification of genome-scale large DNA for advanced therapeutics and synthetic biology, today announced the open US office in North America.  In the midst of the genomic revolution, OriCiro is on a mi...

2022-05-18 22:00 2630

Vela Diagnostics Launches Multiplex PCR-Based Test for Detecting UTI Pathogens and Antimicrobial Resistance Genes

FAIRFIELD, N.J., 17 May, 2022  /PRNewswire/ -- Vela Diagnostics announced today the launch of its new PathoKey® MP UTI ID and AMR PCR Test for research use only (RUO*). This multiplex PCR-based test allows for the in vitro detection and differentiation of 14 pathogens that cause urinary tract in...

2022-05-17 22:00 2899

KAZIA MARKS DIPG AWARENESS DAY; NEW PRECLINICAL DATA IN DIPG TO BE PRESENTED AT ISPNO CONFERENCE

SYDNEY, May 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), a late-stage, oncology-focused drug development company, marks 'DIPG Awareness Day' by recognizing the tireless work of global researchers in this disease, and by calling for an increased focus on childhood ...

2022-05-17 20:00 2511

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

SUZHOU, China, May 15, 2022 /PRNewswire/ -- GeneQuantum Healthcare (Suzhou) Co., Ltd. (hereinafter referred to as "GeneQuantum"), a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won...

2022-05-16 09:00 2952

Kintor Pharma Included in MSCI China Index

SUZHOU, China, May 15, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma," HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced today that the company's stock has been included in the MSCI China Index, e...

2022-05-15 18:28 4383

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma (r/r PTCL) in oral session at the 27th European Hematology Association 2022 (EHA2022)...

2022-05-13 19:09 3411

Yiling Pharmaceutical: Lianhua Qingwen Approved in Nigeria

SHIJIAZHUANG, China, May 12, 2022 /PRNewswire/ -- Yiling Pharmaceutical disclosed Wednesday that it had received the medicine approval document for Lianhua Qingwen Capsules from the National Agency for Food and Drug Administration and Control (NAFDAC),Nigeria. The Product Category is Herbal and ...

2022-05-12 22:43 3107

Gracell Biotechnologies to Present Clinical Data on BCMA/CD19 Dual-targeting CAR-T GC012F in RRMM and B-NHL and CD19/CD7 Dual-directed Allogeneic CAR-T GC502 in B-ALL at EHA2022 Congress

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China , May 12, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of can...

2022-05-12 22:01 3799

BIORCHESTRA Participated in Formulation and Delivery

BOSTON, May 12, 2022 /PRNewswire/ -- BIORCHESTRA is a leading RNA therapeutics company that develops novel RNA-based therapeutics and drug delivery systems for neurodegenerative diseases.  BBB penetration in vivo confocal microscopy clip BIORCHES...

2022-05-12 21:00 2425

Formosa Pharmaceuticals and AimMax Therapeutics Announce Successful Top-Line Results from CPN-301 for the Treatment of Inflammation and Pain after Cataract Surgery

TAIPEI, May 12, 2022 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. (TWO.6838 ) and AimMax Therapeutics, Inc. ( United States) report successful top-line results from CPN-301, the first of two pivotal Phase 3 clinical studies of APP13007, a novelophthalmic...

2022-05-12 20:00 2612

A novel universal antiviral drug introduced in Korea

- Hyundai Bioscience launches CP-COV03 Phase 2 clinical trials - "To be an innovative medicine like penicillin that led to victory in the bacterial war" - Significant changes to the 'vaccine-dependent' virus response system SEOUL, South Korea, May 12, 2022 /PRNewswire/ -- The birth of a universa...

2022-05-12 18:19 3983

Zhimeng Biopharma Announces Dosing of First Subject of Its Novel Antiepileptic Drug Candidate CB03 in First-in-Human Phase I Clinical Trial

SHANGHAI, May 11, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ("Zhimeng"), announced dosing of the first participant in the US Phase I study in healthy subjects of its innovative small-molecule KCNQ2/3 selective opener (CB03), developed for the treatment of refractory epilepsy. CB03 is...

2022-05-12 08:00 2070

Asia's first molecular diagnostics company for women, INEX Innovate receives European CE-IVD Certification for its OvaCis(R) Rapid Test to detect cancer in ovarian cysts.

Revolutionary Ovarian Cancer Rapid Test Available Q4 2022 SINGAPORE, May 11, 2022 /PRNewswire/ -- Known as a pioneer in Asia's women's and fetal health industry,Singapore-based diagnostics developer, INEX Innovate has obtained a CE markfor its lead ovarian cancer product, the OvaCis® Rapid Test....

2022-05-11 22:00 3211
1 ... 220221222223224225226 ... 261